Wolff-Parkinson-White syndrome
Conditions
Interventions
Remifentanil 0.2 microg/kg/min
Remifentanil 0.4 microg/kg/min
Sponsors
Department of Anesthesiology Japanese Red Cross Society Wakayama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: After obtaining written informed consents from the parents, ASA physical status 1 - 2 pediatric patients with Wolff-Parkinson-White syndrome who are scheduled to undergo radiofrequency catheter ablation will be prospectively enrolled in this study. ASA physical status P1 A normal healthy patient P2 A patient with mild systemic disease P3 A patient with severe systemic disease P4 A patient with severe systemic disease that is a constant threat to life P5 A moribund patient who is not expected to survive without the operation P6 A declared brain-dead patient whose organs are being removed for donor purposes
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) obesity 2) allergy to the trial or companion drugs 3) previous history of kidney, and/or liver disease. 4) patients with severe heart diseases including cardiomyopathy, valvulopathy, and congenital cardiac diseases 5) patients deemed unsuitable for the study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After anesthetic induction and catheter insertion, CSACT (calculated sinoatrial conduction time) is measured during first EPS (electrophysiological study). And then, remifentanil is administered at a rate of 0.2 or 0.4 microg/kg/min. Almost 10 minutes after remifentanil administration, second EPS and CSACT measurement is performed. | — |
Secondary
| Measure | Time frame |
|---|---|
| As with mentioned above, CSNRT (corrected sinus node recovery time), RR interval, and AH interval are measured before and during remifentanil administration. | — |
Countries
Japan
Outcome results
None listed